

CLINICAL RESEARCH NEWSLETTER

February 2026 |
Volume II

CORE Fundamentals Training



The CORE Research Fundamentals Training Program equips clinical research professionals with the essential knowledge and tools to conduct high-quality cancer clinical trials across the Georgia NCORP



APRIL 20-21 2026
AT 9:00AM - 4:00 PM

What You'll Learn:

- Cancer Basics 101
- Clinical Trials 101
- Research Roles & Responsibilities
- Informed Consent Process & Documentation
- Regulatory Compliance
- Eligibility Screening & Enrollment
- Safety Reporting (AEs, SAEs, UPs)
- Protocol Interpretation & Compliance
- Good Documentation Practices

Upon completion of this class, you will receive CEU Credits!

CONTACT US



404-523-8735 ext. 4



www.georgiacancerinfo.org

ECOG-ACRIN Audit

Our most recent ECOG-ACRIN audit took place on May 22, 2023, and we remain on a three-year audit cycle. Based on this schedule, we expect formal notification of our next audit in mid-March 2026, as ECOG-ACRIN typically provides approximately six weeks' notice. To support audit readiness, we encourage all sites to begin early preparation. In the coming weeks, the Georgia CORE team will reach out to schedule monitoring visits focused on reviewing documentation completeness, identifying potential gaps, and strengthening overall compliance. If there are specific charts you would like prioritized for review, please let us know, otherwise charts will be selected at random.

We will also distribute any outstanding action items from previously reviewed charts so they can be addressed promptly or discussed with our team if assistance is needed.

Regulatory & Compliance Reminders

- Ensure timely adverse event reporting within protocol-specific windows
 - Verify delegation logs are current and signed
 - Confirm annual human subjects training compliance
 - Monitor remote auditing preparation documentation
- GA CORE remains available for consultation and support.

Contact Info

Alaina Newsome; underberga@sjchs.org
GA NCORP CCDR Program Coordinator

TOPIC	PAGE
CORE Fundamentals/ECOG Audit/Reminders	1
NRG Winter Conference Takeaways	2
Research Based Meeting/Recognition	3
Recently Activated/Recommended Trials	4
All Open and Enrolling CCDR Trials	5
CCDR Trials Pending Activation	6
Test Your Knowledge Quiz/GA NCORP SP	7

CLINICAL RESEARCH NEWSLETTER

February 2026 |
Volume II

NRG Conference Take Aways

Common PRO Challenges

- Electronic Platforms
 - 1.-CTSU Medidata- site personnel role RAVE access
 - 2.-Visiontree (VTOC)-protocol participant access
- Monitoring PRO data assessment expectations and verifying patient data submissions
- Baseline PROs - timeliness of submissions
- PRO Coversheets - Research staff Completes
- Prioritizing PRO Form Data Collection - Primary/secondary PRO Question

News/Update:

CTEP ICF Policy: Commercial Agent Risk Lists

Consent forms will no longer include risk lists for commercial agents obtained commercially used per labeled indication:

- Also Applies to SOC RT
- Reduced site burden
- Improved participant understanding focus on participant-clinical dialogue

CTEP Memo release Dec 8, 2025

Applies to new and actively enrolling trials

Highlighted Study

NRG-CC005 FORTE (Five-orTen-Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps)

Phase III,

Participating Research bases: Alliance, ECOG-ACRIN, NRG, SWOG

Date Activated: 10/6/21

Target Enrollment = 9,500 | Current Accrual = 3943

Enrollment = 48 months

Advancing NIH's Mission Through a Unified Strategy - NIH Priorities

- Training future biomedical scientists
- Replication and reproducibility
- Artificial intelligence
- Promoting research focused on scientifically valid, measurable health outcome
- Shifting to solution-oriented approaches in health disparities research

NRG Developing Trials - Currently N = 30

Brain: 4 (1 NCI approved)	Breast: 1
GI: 6 (2 NCI approved)	GU: 2 (1 NCI-approved)
GYN/DT gyn: 6 (3 NCI-approved)	H&N: 4 (2 NCI-approved)
Lung: 4 (2 NCI-approved)	NCORP: 3 (2 NCI approved)

CLINICAL RESEARCH NEWSLETTER

February 2026 |
Volume II

Upcoming Research Base Meetings*

Research Base	Date	Location
NRG	July 16-18, 2026	Denver, CO
SWOG	April 30-May 2, 2026	San Francisco, CA
	October 8-10, 2026	Chicago, IL
ECOG	May 5-7, 2026	Baltimore, MD
	October 20 - 22, 2026	Philadelphia, PA
URCC	September 25-27, 2026	Niagara Falls, NY
Wake Forest	October 12-14, 2026	Myrtle Beach, SC
UPCOMING ROUTINE AUDITS ¹		
ECOG	TBD FOR 2026	Exact dates and method (onsite vs virtual) are pending.
NRG	TBD	
SWOG	TBD for 2027	
URCC	TBD for 2027	
Wake Forest	TBD for 2027	

*Please contact Shantoria Brown (sbrown@georgiacore.org) to discuss travel funds and audit preparation.

Investigator & Site Recognition

Congratulations to all of the GA031 Investigators and the Northside Hospital Team for achieving the highest accrual in Q4 2025. Their proactive patient screening processes and strong multidisciplinary collaboration have set a model for network excellence.

We also recognize our research nurses and data managers, whose dedication ensures protocol compliance and data integrity across all sites.

EAQ202 - Anticipated Closure to accrual on February 27, 2026

Due to slow enrollment, the DSMB recommended we close accrual on February 27, 2026.

As of February 11, 2026, we need 20 more participants to meet our accrual goal. We encourage you to recruit and enroll eligible BIPOC participants over the next 2 weeks so we can come as close as possible to the overall accrual goal.

CLINICAL RESEARCH NEWSLETTER

February 2026 |
Volume II

Recently Activated and Recommended Trials¹

Research Base	Title	CTSU Activation Date
SWOG	LungMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)	10/22/2025
	S2433: Randomized Phase III Study of Second-Line Chemotherapy with or Without Panitumumab for KRAS Wild Type, Locally Advanced or Metastatic Pancreatic Adenocarcinoma	12/26/2025
ECOG	EAI241: Extended Clinical Follow up and Biospecimen Collection for Patients Enrolled in TAILORx and RxPONDER: A Companion Protocol	12/4/2025
NRG	NRG-GY035: A Randomized Phase III Trial of Carboplatin, Paclitaxel, Pembrolizumab Versus Carboplatin, Paclitaxel, Bevacizumab Versus Carboplatin, Paclitaxel, Pembrolizumab, Bevacizumab in the Treatment of pMMR, TP53 Mutated Advanced or Recurrent Endometrial Cancer	1/12/2026
	NRG-HN015: A Phase II Randomized Trial of Neoadjuvant Chemotherapy or Chemo-Immunotherapy in Patients with Recurrent/Persistent PD-L1 Enriched Squamous Cell Carcinoma of the Head and Neck Undergoing Salvage Surgery (NEOPOLIS)	1/12/2026
Alliance	A232402CD: PAGODA: Randomized Trial of a Proactive Graduated Dose Modification Algorithm for FOLFOX Chemotherapy to Prevent Unplanned Delays	1/06/2026
	A032304: Radioligand Efficacy Comparison by Initial PSA-Response Outcome in Metastatic CRPC with Lutetium 177Lu PSMA RLT (RECIPROCAL)	12/23/2025
Wake Forest	WF-2501CD: Practical Delivery of Geriatric Assessment in Community Oncology Settings (PGA)	12/02/2025
	WF-2502CD: Surgical Thromboprophylaxis Practices in Oncology Patients within the NCORP Network (STOP-VTE)	12/02/2025

CLINICAL RESEARCH NEWSLETTER

February 2026 |
Volume II

ALL OPEN AND ENROLLING CANCER CARE DELIVERY RESEARCH (CCDR) TRIALS¹

Research Base	Title	CTSU Activation Date
Alliance	A232301CD: AYA Access Study: An Enhanced eHealth and Chat-Bot Enabled Delivery Model for Clinical Genetic Services in Community AYA Cancer Patients	9/26/2025
	A232402CD: PAGODA: Randomized Trial of a Proactive Graduated Dose Modification Algorithm for FOLFOX Chemotherapy to Prevent Unplanned Delays	1/06/2026
ECOG-ACRIN	EAQ221CD: Mobile Health for Adherence in Breast Cancer Patients (CONCURxP) Deemed high priority by the Executive Committee.	10/31/2023
	EAQ222CD: Cost Communication and Financial Navigation in Cancer Patients (COSTCOM) Sites must receive approval prior to initiating any study start-up activities.	2/29/2024
SWOG	S2417CD: A Pragmatic Randomized Controlled Trial To Evaluate The Effectiveness of an Intervention called Current Together After Cancer (CTAC) to Promote Guideline-Concordant Colorectal Cancer Surveillance	8/4/2025
Wake Forest	WF-1805CD: Implementation and Effectiveness Trial of HN-STAR Participant enrollment closed as of 2/13/2025, but practice (non-patient) enrollment is now ongoing.	8/10/2020
	WF-2301CD: Multi-site Community Oncology Planning for the CONNECT Intervention Targeting Lung Cancer Caregivers ² Closed to accepting new sites. Contact Jess Sheedy (jsheedy@wakehealth.edu) to get on the waitlist.	7/2/2024
	WF-2303CD: Understanding and Enhancing Health-Related Social Needs (HRSN) Screening Among Community Oncology Practice Closed to accepting new sites. Contact Jess Sheedy (jsheedy@wakehealth.edu) to get on the waitlist.	7/23/2024
	WF-2502CD: Surgical Thromboprophylaxis Practices in Oncology Patients within the NCORP Network (STOP-VTE)	12/02/2025

CLINICAL RESEARCH NEWSLETTER

February 2026 |
Volume

TRIALS PENDING ACTIVATION

Research Base	Title
ECOG-ACRIN	EAQ241CD: FinFit: Addressing Financial Hardship in AYA Cancer Survivors
	EA6232: Phase II Double-Blind Trial of Sulforaphane for Therapeutic Prevention of Melanoma in Patients with Multiple Atypical Nevi and a Prior History of Melanoma
	EAQ181: Randomized Controlled Trial of FoRtitude: Targeted eHealth Intervention to Reduce Fear of Recurrence Among Breast Cancer Survivors in Community Oncology Settings
	EAQ161CD: Biomarker Testing in Common Solid Cancers: An Assessment of Current Practices in Precision Oncology in the Community Setting
Alliance	A212101: Evaluation of Provider vs. Patient Mediated Cascade Genetic Testing of First-Degree Relatives of Patients With Newly Diagnosed Colorectal Cancer
	A222302: Family Communications After Genetic Testing
SWOG	S2424CD: Testing an Educational Program to Improve Goals of Care Conversations Between Patients and Their Care Teams
Wake Forest	WF-2300CD: Practice Survey for Multi-site Community Oncology Planning for the CONNECT Intervention Targeting Lung Cancer Caregivers
URCC	URCC-18004CD: Understanding the Impact of Drug Shortages on Oncology Care Delivery

CLINICAL RESEARCH NEWSLETTER

February 2026 |
Volume II

TEST OF YOUR KNOWLEDGE QUIZ!

The first person to answer correctly will receive Georgia NCORP swag and a shout-out in the next issue!
Send your responses to kdixon@georgiacore.org.

1. Which of the following best defines a Phase III oncology clinical trial?

- A. Determines safe dosage range
- B. Compares a new treatment to standard of care
- C. Explores biological mechanisms
- D. Tests treatment in healthy volunteers

2. In the TNM staging system, what does the "N" represent?

- A. Number of prior treatments
- B. Necrosis of the tumor
- C. Regional lymph node involvement
- D. New tumor growth

3. Which biomarker is commonly associated with targeted therapy in breast cancer?

- A. HER2
- B. PSA
- C. AFP
- D. CA-125

Georgia CORE SharePoint Site Relaunch

We are excited to announce the relaunch of the Georgia CORE SharePoint site, your centralized hub for program resources and updates. This site is designed to streamline communication and provide easy access to key materials, including Georgia CORE templates, the GA NCORP calendar for site visits, audits, and conferences, the accrual dashboard, and other important program announcements.

We encourage all sites to bookmark the portal and begin using it as your primary reference for program tools and information. This is not meant to be another place to check, it is meant to replace the scattered emails and attachments that slow everyone down. Start using it this week so it actually becomes part of your workflow.